Organovo Holdings, Inc.

The Advanced Regenerative Manufacturing Institute (ARMI) | BioFabUSA highlights Organovo subsidiary, Samsara Sciences, as a new member committed to the development of industry-wide standards for cellular raw materials. Read the full article here http://bit.ly/2N199WF

It is estimated that 12% of the global population has NASH. Yet, there are still no approved drugs to treat this silent disease. Learn more about this growing epidemic and help spread awareness today #NASHDay International NASH Day #NAFLD https://www.youtube.com/watch?v=k1U7_l9kORY

How can #bioprinting be used to advancement #regenmed and #raredisease research? CEO, Taylor Crouch explains in this month's issue of PharmaVOICE. http://bit.ly/2J2DF4e

Today our president and CEO, Taylor Crouch, has been appointed as a member of the Biocom board along with three other leaders in the California #lifescience industry. http://bit.ly/2J02MES

Data presented at EASL - The Home of Hepatology International Liver Congress on Organovo's 3D bioprinted liver tissue model for #NAFLD provides strong support for its application in high-value drug profiling, including the possible creation of patient or population-specific variants. http://bit.ly/2GWqXCU #NASH #ILC2018

Organovo at EASL 2018 International Liver Congress in Paris this week. Stop by poster THU-503 or find us in the Biotech Village to learn how 3D bioprinted liver tissue is being used to study NAFLD. https://ilc-congress.eu/

Samsara Sciences announces multi-year supply agreement with Lonza Bioscience Solutions http://bit.ly/2I1Z60w

Organovo to Present at H.C. Wainwright NASH Investor Conference on March 19 at 2:40pm ET - http://bit.ly/2FHT6Jr Live webcast will be available on our events page.

Organovo at the Society of Toxicology Annual Meeting in San Antonio. Stop by poster 1383/P481 and booth 763 to learn about our advances in preclinical testing and disease modeling #2018SOT #ToxExpo

Login now for Organovo's presentation at the 30th Annual Roth Conference - webcast begins at 7:30am PT

We're getting closer to being able to 3D print a new liver. Or part of it, at least. #FT50ideas

Treatments for rare diseases often require novel approaches. Using our proprietary bioprinting platform, we are working to develop a liver tissue patch for rare metabolic diseases such as alpha 1 antitrypsin and FAH deficiency. Watch this video to learn more about #Alpha1 and share to help raise awareness. #ShowYourRare #RareDiseaseDay http://bit.ly/2F1ryBw